The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.
A promising vaccine candidate for Rift Valley fever (RVF) has been advanced into a phase 2 trial in Kenya, the first time that a shot has reached this stage of development in a country wher